Folate Conjugate for Monocyte Imaging and Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to diagnose and treat disease states mediated by monocytes, as the expression of folate receptors on these cells is unknown, and existing approaches do not efficiently target or alter monocyte function.
Innovation Solution
Development of ligands that bind to monocytes, such as folate receptor-binding ligands or monoclonal antibodies, conjugated with imaging agents or cytotoxins to diagnose or treat monocyte-mediated diseases by redirecting immune responses, inactivating, or killing monocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging agents are used, then general tissue imaging is possible, but specific targeting of monocytes cannot be achieved
Solution Approach 1:
The patent combines a folate receptor-binding ligand with an imaging agent to create a conjugate that merges the specific targeting capability of the ligand with the imaging functionality of the agent, enabling specific visualization of monocytes while maintaining diagnostic accuracy
Solution Approach 2:
The folate receptor-binding ligand acts as an intermediary that mediates between the imaging agent and the monocyte surface, allowing the imaging agent to specifically bind to and visualize monocytes without directly interacting with the cell surface receptors
2Difficulty of detecting and measuring
If folate receptor-binding ligands are conjugated with imaging agents, then specific monocyte targeting is achieved, but the complexity of the diagnostic method increases
Solution Approach 1:
The conjugate is prepared in advance before administration to the patient, allowing the ligand and imaging agent to be pre-assembled and quality-controlled, which simplifies the actual diagnostic procedure to a single administration and imaging step
3Reliability
If ligands are conjugated to cytotoxins to kill monocytes, then monocyte-mediated disease can be treated, but off-target effects may occur
Solution Approach 1:
The cytotoxic agent is delivered with high local concentration specifically to monocytes through the folate receptor-targeting ligand, while maintaining low systemic concentration, thereby achieving effective monocyte killing while minimizing off-target effects on other cell types
Solution Approach 2:
The high affinity of folate receptor-binding ligands for monocytes is exploited to deliver cytotoxic agents preferentially to pathogenic monocytes, converting the potential harm of cytotoxicity into a beneficial therapeutic effect by concentrating the toxic effect only where needed
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for accurate diagnosis and treatment of monocyte-mediated diseases by specifically targeting and altering monocyte function, reducing disease symptoms and preventing progression.
Implementation Method 1
The folate receptor is a 38 KD GPI-anchored protein that binds the vitamin folic acid with high affinity
Implementation Method 2
In still another embodiment, the imaging agent comprises a chromophore selected from the group consisting of fluorescein, Oregon Green, rhodamine, phycoerythrin, Texas Red, and AlexaFluor 488
Implementation Method 3
In another embodiment, the imaging agent comprises a metal chelating moiety that binds an element that is a radionuclide
Data Source
AI summary
The invention relates to a method of treating or diagnosing a disease state mediated by monocytes. The method utilizes a composition comprising a conjugate or complex of the general formulaAb-Xwherein the group Ab comprises a ligand that binds to monocytes, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering monocyte function, and when the conjugate is being used for diagnosing the disease state, the group X comprises an imaging agent.